[1]刘伟平,官凡琪,宋耀辉,等.慢性粒细胞白血病患者BCR-ABL融合基因P210表达对病程判断和预后评估的临床价值[J].现代检验医学杂志,2019,34(05):12-15.[doi:10.3969/j.issn.1671-7414.2019.05.004]
　LIU Wei-ping,GUAN Fan-qi,SONG Yao-hui,et al.Clinical Value of BCR-ABL Fusion Gene P210 Expression of Patients with Chronic Myeloid Leukemia for Course Judgment and Prognosis Evaluation[J].Journal of Modern Laboratory Medicine,2019,34(05):12-15.[doi:10.3969/j.issn.1671-7414.2019.05.004]
点击复制

慢性粒细胞白血病患者BCR-ABL融合基因P210表达对病程判断和预后评估的临床价值()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第34卷
期数:
2019年05期
页码:
12-15
栏目:
论著
出版日期:
2019-10-29

文章信息/Info

Title:
Clinical Value of BCR-ABL Fusion Gene P210 Expression of Patients with Chronic Myeloid Leukemia for Course Judgment and Prognosis Evaluation
文章编号:
1671-7414(2019)05-012-04
作者:
刘伟平1; 官凡琪2; 宋耀辉1; 阮艳秋1
(1.自贡市第一人民医院检验科,四川自贡 643000; 2.遵义医科大学医学与科技学院,贵州遵义 563000)
Author(s):
LIU Wei-ping1; GUAN Fan-qi2; SONG Yao-hui1; RUAN Yan-qiu1
(1.Department of Clinical Laboratory,the First People's Hospital of Zigong City,Sichuan Zigong 643000,China; 2.School of Medicine and Science Technology,Zunyi Medical University,Guizhou Zunyi 563000,China)
关键词:
慢性粒细胞白血病;  BCR-ABL P210;  病程判断
分类号:
R557.3; Q786
DOI:
10.3969/j.issn.1671-7414.2019.05.004
文献标志码:
A
摘要:
目的 探讨BCR-ABL融合基因P210的表达与外周血象、α-羟丁酸脱氢酶(HBDH)、乳酸脱氢酶(LDH)和血糖(GLU)对慢性粒细胞白血病(CML)的病程判断和预后评估中的临床意义。方法 收集2017年4月～2018年5月在自贡第一人民医院初诊确诊的慢性粒细胞白血病患者外周血标本; 采用实时荧光定量PCR方法测定30例慢性粒细胞白血病患者外周血BCR-ABL融合基因P210表达水平。同时测定GLU、LDH、HBDH、血清钾(K+)和尿酸(UA)的含量,并结合患者血象进行综合分析。结果30例慢性粒细胞白血病患者BCR-ABL融合基因P210阳性表达率为93.3%,白血病不同分期BCR-ABL融合基因P210表达量差异有统计学意义(P<0.05)。其中13例慢性期患者采用酪氨酸激酶抑制剂(伊马替尼)治疗1年后,BCR-ABL P210阳性率由100%降低为23.1%(3/13)。不同时期慢性粒细胞白血病患者在白细胞数量(WBC)、中性粒细胞/淋巴细胞比值(NEU/LYM)、血红蛋白(HGB)差异有统计学意义(P<0.05)。结论 BCR-ABL P210表达水平结合外周血WBC、HGB、NEU/LYM、GLU,LDH的检测,有助于慢性粒细胞白血病病程判断和预后评估。
Abstract:
Objective To investigate the clinical significance of the expression of BCR-ABL fusion gene P210 and peripheral blood images,lactate dehydrogenase(LDH),alpha-hydroxybutyrate dehydrogenase(HBDH),serumglucose(GLU),K+ and uric acid(UA)in the course judgment and prognosis evaluation of chronic myelogenous leukemia(CML).Methods Peripheral blood samples of 30 CML patients diagnosed in the First People's Hospital of Zigong City from April 2017 to May 2018 were collected.The expression level of BCR-ABL fusion gene P210 in peripheral blood of 30 CML patients was determined by Real Time-PCR.Serum GLU,LDH and HBDH dehydrogenase were determinedsimultaneously and combined with blood and bone marrow images of CML patients for comprehensive analysis.Results The positive expressionrate of BCR-ABL fusion gene P210 in 30 CML patients was 93.3%,and the expression level of bcr-abl fusion gene P210 in different stages of leukemia was statistically significant(P<0.05).After 1 year of treatment with tyrosine kinase inhibitor(imatinib),the positive rate of bcr-abl P210 in 13 patients withCML decreased from 100% to 23.1%(3/13).There were statistically significantdifferences in the number of WBC,the number of neutrophils,and the ratio of neutrophils/lymphocytes between chronic myelogenous leukemia patients at differentstages(P<0.05).Conclusion The expression of BCR-ABL P210 combined with WBC,hemoglobin,NEU/LYM,serum GLU and LDH is helpful for the course judgement and prognosis evaluation of CML.

参考文献/References:

[1] 董鑫.FoxM1调控DAN损伤修复在慢性髓性白血病伊马替尼耐药中的作用及机制研究[D].济南:山东大学,2017. DONG Xin.The role of FoxM1 induced DAN damage response in imatinibresistant chronic myeloid leukemia and it's regulatory mechanisms[D].Jinan:Shandong University,2017. [2] 江锦红.伊马替尼治疗新诊断和干扰素治疗失败的慢性髓性白血病疗效比较[D].杭州:浙江大学,2015. JIANG Jinhong.Imatinib mesylate for chronicpha-se chronic myeloidleukemia:initial treatment versus after failure of INF-α[D].Hangzhou:Zhejiang University,2015. [3] HUGHES A,YONG A S M.Immune effector recovery in chronic myeloid leukemia and treatment-free remission[J].Frontiers in Immunology,2017,8:469. [4] AYATOLLAHI H, KERAMATI M R, SHIRDEL A,et al.BCR-ABL fusion genes andlaboratory findings in patients with chronic myeloid leukemia in northeast Iran[J].Caspian Journal of Internal Medicine,2018,9(1):65-70. [5] BACCARANI M,DEININGER M W,ROSTI G,et al.European leukemia Net recommendations for the management of chronic myeloidle 1eukemia:2013[J].Blood,2013,122(6):872-884. [6] WANG Wenjun,ZHENG Chaofeng,LIU Zhuang,et al.Droplet digital PCR for BCR/ABL(P210)detection of chronic myeloid leukemia:a high sensitive method of the minimal residual disease and disease progression[J].European Journal of Haematology,2018,101(3):291-296. [7] WANG Rui,CONG Yue,LI Caili,et al.Predictive value of early molecularresponse for deep molecular response in chronic phase of chronic myeloid leukemia[J].Medicine,2019,98(15):e15222. [8] SHANMUGANATHAN N,HUGHES T P.Molecular monitoring in CML:how deep?Howoften?How should it influence therapy?[J].Hematology,2018,2018(1):168-176. [9] 邹媛,杜翠,陈红梅,等.BCR/ABL融合基因少见型实时荧光PCR定量检测在慢性髓系白血病中的应用[J].中国实验血液学杂志,2017,25(4):1016-1021. ZOU Yuan,DU Cui,CHEN Hongmei,et al.Applica-tion of real-time quantitative PCR in detecting atypical BCR/ABL transcripts in chronic myelocyticleukemia[J].Journal of Experimental Hematology,2017,25(4):1016-1021. [10] PAN Jia,MIAO Dong.Germacrone reverses adriamycin resistance inhuman chronic myelogenous leukemia K562/ADM cells by suppressing MDR1 gene/P-glycoprotein expression[J].Chemico-Biological Interactions,2018,288:32-37.

相似文献/References:

[1]陈 静,鞠 镇.一代和二代酪氨酸激酶抑制剂治疗 对CML染色体的影响及疗效[J].现代检验医学杂志,2015,30(01):91.[doi:10.3969/j.issn.1671-7414.2015.01.025]
　CHEN Jing,JU Zhen.Chromosome's Influence and Curative Effect on First and Second Generation Tyrosine Kinase Inhibitor Therapy to CML[J].Journal of Modern Laboratory Medicine,2015,30(05):91.[doi:10.3969/j.issn.1671-7414.2015.01.025]
[2]张文静a,郑维威a,宋闿迪b,等.慢性粒细胞白血病患者骨髓单个核细胞中CaMKⅡγ在疾病不同阶段的表达及分子机制[J].现代检验医学杂志,2018,33(03):8.[doi:10.3969/j.issn.1671-7414.2018.03.003]
　ZHANG Wen-jinga,ZHENG Wei-weia,SONG Kai-dib,et al.Expression and Molecular Mechanism of CaMK II Gamma of Bone Marrow Mononuclear Cells in Different Stages of Patients with CML[J].Journal of Modern Laboratory Medicine,2018,33(05):8.[doi:10.3969/j.issn.1671-7414.2018.03.003]

备注/Memo

备注/Memo:
值基金项目:四川省医学科研课题计划(编号Q18025)。 作者简介:刘伟平(1980-),男,硕士,副主任技师,主要从事免疫学及分子生物学检验诊断研究,E-mail: freeliuweiping@163.com。
更新日期/Last Update: 2019-10-20